GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Research & Development

Eledon Pharmaceuticals (FRA:2TK) Research & Development : €27.38 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Eledon Pharmaceuticals's Research & Development for the three months ended in Mar. 2024 was €6.82 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €27.38 Mil.

Eledon Pharmaceuticals Research & Development Historical Data

The historical data trend for Eledon Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Research & Development Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.32 5.04 21.01 25.56 27.80

Eledon Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.58 6.65 7.43 6.48 6.82

Eledon Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €27.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals  (FRA:2TK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Eledon Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Eledon Pharmaceuticals (FRA:2TK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Research & Development
Comparable Companies
PASG GANX BOLT LPTX HOOK PRTG ICCC RZLT RAIN DTIL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ELDN:USA
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Website
https://www.eledon.com
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals (FRA:2TK) Headlines

No Headlines